Belinostat (trade name Beleodaq, previously known as PXD101) is a histone deacetylase inhibitor drug developed by TopoTarget for the treatment of hematological malignancies and solid tumors.
via Wikipedia infobox
via PubMed
Belinostat (trade name Beleodaq, previously known as PXD101) is a histone deacetylase inhibitor drug developed by TopoTarget for the treatment of hematological malignancies and solid tumors.
It was approved in July 2014 by the US FDA to treat peripheral T-cell lymphoma.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).